• Small Molecules
      • Discovery
        Development
        Manufacturing
    • Biologics
      • Discovery
        Development & Manufacturing
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery

      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

        Know More
        Know More
    • Industries
    • Emerging Biopharma

      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

        Know More
        Know More
    • Dedicated Centers

      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

        Know More
        Know More
    • Center for Advanced Protein Studies (CAPS)

      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

        Know More
        Know More
    • Investors
      Corporate Governance
  • Careers

Blogs

Choose from a variety of resources to get a better understanding of Syngene’s point of view, expertise or approach to drug discovery, development and manufacturing to ensure client success.

Resource Types

Paws, Pills and Progress - CRDMO’s pivotal role
As I stepped into the conference hall in Boston, I overheard an investor say, “The next billion-dollar biotech might just come from the animal health sector.
26th Jun, 2025
Read
Reducing variability in gene expression: Bottlenecks and Solutions
Explore challenges in reducing the variability in gene expression in traditional cell line development (CLD) and the power of the transposon system to address these inefficiencies.
23rd Jan, 2025
Read
Quantifying a biomarker in mice brain for treating mood and anxiety disorders
A robust LC-MS-based quantitative method developed at Syngene to measure biomarker 2-AG in mice brain tissues for treating mood and anxiety disorders.
18th Oct, 2024
Read
Risk assessment strategy for nitrosamine drug substance-related impurities
The potential causes of nitrosamine drug substance-related impurities and Syngene’s strategic framework for identification and management of these impurities to meet regulatory guidelines for product safety.
2nd Sep, 2024
Read
Innovation at Syngene: Translatable models for improving cancer research
Syngene has developed orthotopic models validated against the standard of care and tumor models with 3D culture, which can help improve translatability and clinical relevance in cancer research.
12th Jun, 2024
Read
pDNA and mRNA manufacturing in the age of Precision Therapies: The role of CDMOs
Challenges in pDNA manufacturing and why CDMOs are best suited for supplying pDNA for Precision Therapies.
28th Nov, 2023
Read
Leveraging High Throughput Screening services to accelerate drug discovery and development
The many applications of HTS and how it has evolved beyond lead identification and candidate optimization today.
18th Aug, 2023
Read
Harnessing the power of induced proximity-based drugs and precision medicine for treating cancer
How Syngene is supporting clients in treating cancer using targeted protein degradation, protein stabilization approaches, and precision medicine therapies.
19th Jun, 2023
Read
Five questions that determine the success of your PROTAC programs
Challenges in developing PROTACs and critical questions that need to be addressed to move PROTAC molecules from Target to IND successfully.
18th Oct, 2022
Read
Solving problems with science: Gene to GMP-grade clinical supply in nine months
How Syngene’s proprietary data platform is safely and efficiently reducing the time taken to produce mAbs from gene to GMP-grade clinical supply by several months.
6th Sep, 2022
Read

Explore more

Blog

Read our blogs for industry insights and best practices…

More
More

Instavisit

Visit Syngene virtually via our 360 degree lab tours…

More
More

Webinar

View our webinars on cutting edge science topics and insights…

More
More

Viewpoint

Read our latest Viewpoints and White papers….

More
More

Get in touch

Sign-up for our newsletter

© 2025. Syngene International Limited

Linkedin-in Youtube Facebook-f

Quick links

Business

Get in touch

Other links
Linkedin-in Youtube Facebook-f

© 2025. Syngene International Limited

To view or email, Please share your details view

Download PDF
Download PDF

Your browser does not support this function.

To download, Please share your details

To view or email, Please share your details view

To download, Please share your details